Subcutaneous hormone implants for the control of climacteric symptoms. A prospective study.
55 postmenopausal women on established hormone replacement therapy were treated with either oestradiol and testosterone implants or placebo at the time of return of climacteric symptoms. Their response to therapy was assessed prospectively. The statistically highly significant levels of symptom relief that followed an oestradiol and testosterone implant were contrasted sharply with the lack of any significant relief with placebo. Despite the success of oestradiol and testosterone implants in relieving symptoms of the climacteric, symptoms returned once the treatment was stopped. Evidence is presented that it is the fall in hormone levels rather than the level itself that provokes the return of climacteric symptoms.
D000328:Adult; D002979:Climacteric / Q000187:drug effects; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy; D004311:Double-Blind Method; D004343:Drug Implants; D004958:Estradiol / Q000008:administration & dosage* / Q000494:pharmacology; D005260:Female; D006801:Humans; D007989:Libido / Q000187:drug effects; D011446:Prospective Studies; D012894:Sleep Stages / Q000187:drug effects; D013577:Syndrome; D013739:Testosterone / Q000008:administration & dosage* / Q000494:pharmacology; D013997:Time Factors; D014522:Urethral Diseases / Q000188:drug therapy
D004343:Drug Implants; D013739:Testosterone; D004958:Estradiol